CO6382171A2 - Compuestos de pirazol y triazol sustituidos como inhibiores de ksp - Google Patents

Compuestos de pirazol y triazol sustituidos como inhibiores de ksp

Info

Publication number
CO6382171A2
CO6382171A2 CO09048059A CO09048059A CO6382171A2 CO 6382171 A2 CO6382171 A2 CO 6382171A2 CO 09048059 A CO09048059 A CO 09048059A CO 09048059 A CO09048059 A CO 09048059A CO 6382171 A2 CO6382171 A2 CO 6382171A2
Authority
CO
Colombia
Prior art keywords
pirazol
ksp
inhibitors
compounds replaced
triazol compounds
Prior art date
Application number
CO09048059A
Other languages
English (en)
Inventor
Yi Xia
Kris Mendenhall
Paul A Barsanti
Annette Walter
David Duhl
Paul Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6382171A2 publication Critical patent/CO6382171A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer nuevos compuestos de pirazol y triazol sustituidos de la fórmula (I), y sales farmacéuticamente aceptables, ésteres o pro-fármacos de los mismos, composiciones de los derivados junto con vehículos farmacéuticamente aceptables, y usos de los mismos.
CO09048059A 2006-11-13 2009-05-12 Compuestos de pirazol y triazol sustituidos como inhibiores de ksp CO6382171A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
CO6382171A2 true CO6382171A2 (es) 2012-02-15

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09048059A CO6382171A2 (es) 2006-11-13 2009-05-12 Compuestos de pirazol y triazol sustituidos como inhibiores de ksp

Country Status (32)

Country Link
US (2) US8129358B2 (es)
EP (1) EP2091926B1 (es)
JP (1) JP5264755B2 (es)
KR (1) KR20090081020A (es)
CN (1) CN101558049B (es)
AR (1) AR063805A1 (es)
AU (1) AU2007323998B2 (es)
BR (1) BRPI0719002A2 (es)
CA (1) CA2668661A1 (es)
CL (1) CL2007003272A1 (es)
CO (1) CO6382171A2 (es)
CR (1) CR10787A (es)
DO (1) DOP2009000106A (es)
EA (1) EA017748B1 (es)
EC (1) ECSP099326A (es)
ES (1) ES2557478T3 (es)
GE (1) GEP20125389B (es)
GT (1) GT200900122A (es)
HN (1) HN2009000968A (es)
IL (1) IL198471A0 (es)
MA (1) MA30959B1 (es)
MX (1) MX2009005071A (es)
NI (1) NI200900084A (es)
NO (1) NO20092226L (es)
NZ (1) NZ576640A (es)
PE (1) PE20081169A1 (es)
SM (1) SMP200900045B (es)
TN (1) TN2009000178A1 (es)
TW (1) TW200831480A (es)
UA (1) UA97256C2 (es)
WO (1) WO2008063912A1 (es)
ZA (1) ZA200902940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
KR20090097210A (ko) * 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
EA201201404A1 (ru) * 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
MX355439B (es) * 2012-12-05 2018-04-18 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
WO2015084763A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
EP3386973B1 (en) * 2015-12-11 2020-08-12 Syngenta Participations AG Pesticidally active 1,2,4-triazole derivatives
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
TW200300078A (en) 2001-11-08 2003-05-16 Univ Chicago Method of treating disorder related to high cholesterol concentration
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7262186B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
EP1465896A4 (en) 2001-12-06 2006-01-11 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
JP4597519B2 (ja) 2001-12-06 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害薬
JP2005516004A (ja) * 2001-12-07 2005-06-02 ヴァージニア コモンウェルス ユニバーシティ 新形成の治療
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
CA2478068C (en) 2002-03-08 2011-02-08 Merck & Co., Inc. Dihydropyrazole compounds useful for treating or preventing cancer
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485148A1 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003245453B2 (en) 2002-06-14 2008-08-14 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
US20070032536A1 (en) 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
AU2005233576A1 (en) 2004-04-06 2005-10-27 Novartis Vaccines And Diagnostics, Inc. Mitotic kinesin inhibitors
ATE404536T1 (de) 2004-05-21 2008-08-15 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
WO2006002236A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
MX2007004699A (es) 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Derivados de indol y bencimidazol.
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
NZ576640A (en) 2011-10-28
CL2007003272A1 (es) 2008-03-24
EA017748B1 (ru) 2013-02-28
US7902240B2 (en) 2011-03-08
CA2668661A1 (en) 2008-05-29
KR20090081020A (ko) 2009-07-27
GEP20125389B (en) 2012-01-25
JP2010509365A (ja) 2010-03-25
US8129358B2 (en) 2012-03-06
JP5264755B2 (ja) 2013-08-14
US20080200462A1 (en) 2008-08-21
AR063805A1 (es) 2009-02-18
TW200831480A (en) 2008-08-01
WO2008063912A1 (en) 2008-05-29
EP2091926A1 (en) 2009-08-26
SMP200900045B (it) 2010-03-01
ES2557478T3 (es) 2016-01-26
NI200900084A (es) 2010-01-29
AU2007323998B2 (en) 2011-09-22
AU2007323998A1 (en) 2008-05-29
GT200900122A (es) 2011-09-14
UA97256C2 (ru) 2012-01-25
ECSP099326A (es) 2009-06-30
EP2091926B1 (en) 2015-10-21
BRPI0719002A2 (pt) 2013-12-17
HN2009000968A (es) 2011-10-25
MX2009005071A (es) 2009-05-25
CR10787A (es) 2009-07-02
IL198471A0 (en) 2010-02-17
DOP2009000106A (es) 2009-05-31
CN101558049B (zh) 2012-08-15
EA200900631A1 (ru) 2009-12-30
CN101558049A (zh) 2009-10-14
TN2009000178A1 (en) 2010-10-18
ZA200902940B (en) 2010-05-26
SMAP200900045A (it) 2009-07-14
PE20081169A1 (es) 2008-09-24
NO20092226L (no) 2009-08-12
MA30959B1 (fr) 2009-12-01
US20100034813A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
ECSP099326A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
DOP2009000169A (es) Derivados ciclados como inhibidores de eg-5
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
ECSP088549A (es) Nuevos derivados de pirrol fusionado
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY31189A1 (es) Compuestos heterocíclicos
TW200612958A (en) Substituted imidazole derivatives
ECSP055729A (es) Nuevos inhibidores biciclicos de la lipasa sensible a hormonas
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
CR11653A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
SV2011003916A (es) Nuevas lactamas como inhibidores de beta secretasa
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
AR061740A1 (es) Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen
GT200800296A (es) Derivados de ácido fenilacético
CU20100125A7 (es) Derivados bis-(sulfonilamino) para uso en terapia

Legal Events

Date Code Title Description
FC Application refused